Skip navigation
  • 中文
  • English

DSpace CRIS

  • DSpace logo
  • Home
  • Organizations
  • Researchers
  • Research Outputs
  • Explore by
    • Organizations
    • Researchers
    • Research Outputs
  • Academic & Publications
  • Sign in
  • 中文
  • English
  1. NTU Scholars
  2. 醫學院
  3. 病理學科所
Please use this identifier to cite or link to this item: https://scholars.lib.ntu.edu.tw/handle/123456789/470378
Title: Predictive and prognostic values of tau and ERCC1 in advanced breast cancer patients treated with paclitaxel and cisplatin
Authors: YU-YUN SHAO 
KUAN-TING KUO 
Hu F.-C.
YEN-SHEN LU 
CHIUN-SHENG HUANG 
JAU-YU LIAU 
Lee W.-C.
CHIUN HSU 
WEN-HUNG KUO 
KING-JEN CHANG 
CHING-HUNG LIN 
ANN-LII CHENG 
Issue Date: 2010
Journal Volume: 40
Journal Issue: 4
Start page/Pages: 286-293
Source: Japanese Journal of Clinical Oncology
Abstract: 
Objective: We studied tau and excision repair cross-complementing 1 expression to evaluate their predictive values in advanced breast carcinoma patients. Methods: Patients treated with paclitaxel and cisplatin as the first-line chemotherapy for locally advanced or metastatic breast cancer were enrolled. The expression levels of tau and excision repair cross-complementing 1 were assessed by immunohistochemistry and examined for their associations with treatment response and survival. Results: Fifty-four patients were included in this study. Despite the strong association between tau expression and lower histological grade and estrogen receptor expression, tau expression remained an independent predictor for a lower response rate in multivariate analysis (odd ratio = 0.24, P = 0.02). However, tau expression was a predictor for longer overall survival in both univariate analysis (median, 57.5 vs. 30.4 months, P = 0.02) and multivariate analysis (hazard ratio = 0.36, P = 0.008). Excision repair cross-complementing 1 was not associated with treatment response or overall survival. Conclusions: Tau expression but not excision repair cross-complementing 1 in advanced breast cancer predicts poor response to combination chemotherapy of paclitaxel and cisplatin. However, tau expression is significantly associated with longer overall survival. ? The Author (2010). Published by Oxford University Press. All rights reserved.
URI: https://www.scopus.com/inward/record.uri?eid=2-s2.0-77951241525&doi=10.1093%2fjjco%2fhyp184&partnerID=40&md5=b0b4679eca06c9993866930317fbde99
https://scholars.lib.ntu.edu.tw/handle/123456789/470378
ISSN: 0368-2811
DOI: 10.1093/jjco/hyp184
SDG/Keyword: cisplatin; estrogen receptor; excision repair cross complementing protein 1; hormone; paclitaxel; progesterone receptor; tau protein; antineoplastic agent; cisplatin; DNA binding protein; endonuclease; ERCC1 protein, human; paclitaxel; tau protein; tumor marker; adjuvant therapy; adult; advanced cancer; aged; article; breast carcinoma; cancer adjuvant therapy; cancer combination chemotherapy; cancer grading; clear cell carcinoma; drug dose regimen; drug dose sequence; gene expression; human; immunohistochemistry; low drug dose; major clinical study; mucinous carcinoma; multiple cycle treatment; overall survival; prediction; prognosis; survival time; treatment response; biosynthesis; breast tumor; disease free survival; drug resistance; female; genetics; Kaplan Meier method; metabolism; middle aged; phase 2 clinical trial; retrospective study; treatment outcome; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cisplatin; Clinical Trials, Phase II as Topic; Disease-Free Survival; DNA-Binding Proteins; Drug Resistance, Neoplasm; Endonucleases; Female; Humans; Immunohistochemistry; Kaplan-Meiers Estimate; Middle Aged; Paclitaxel; Prognosis; Retrospective Studies; tau Proteins; Treatment Outcome; Tumor Markers, Biological
[SDGs]SDG3
Appears in Collections:病理學科所

Show full item record

SCOPUSTM   
Citations

25
checked on Jan 26, 2023

WEB OF SCIENCETM
Citations

23
checked on Jan 22, 2023

Page view(s)

9
checked on Oct 29, 2022

Google ScholarTM

Check

Altmetric

Altmetric

Related Items in TAIR


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.

臺大位居世界頂尖大學之列,為永久珍藏及向國際展現本校豐碩的研究成果及學術能量,圖書館整合機構典藏(NTUR)與學術庫(AH)不同功能平台,成為臺大學術典藏NTU scholars。期能整合研究能量、促進交流合作、保存學術產出、推廣研究成果。

To permanently archive and promote researcher profiles and scholarly works, Library integrates the services of “NTU Repository” with “Academic Hub” to form NTU Scholars.

總館學科館員 (Main Library)
醫學圖書館學科館員 (Medical Library)
社會科學院辜振甫紀念圖書館學科館員 (Social Sciences Library)

開放取用是從使用者角度提升資訊取用性的社會運動,應用在學術研究上是透過將研究著作公開供使用者自由取閱,以促進學術傳播及因應期刊訂購費用逐年攀升。同時可加速研究發展、提升研究影響力,NTU Scholars即為本校的開放取用典藏(OA Archive)平台。(點選深入了解OA)

  • 請確認所上傳的全文是原創的內容,若該文件包含部分內容的版權非匯入者所有,或由第三方贊助與合作完成,請確認該版權所有者及第三方同意提供此授權。
    Please represent that the submission is your original work, and that you have the right to grant the rights to upload.
  • 若欲上傳已出版的全文電子檔,可使用Sherpa Romeo網站查詢,以確認出版單位之版權政策。
    Please use Sherpa Romeo to find a summary of permissions that are normally given as part of each publisher's copyright transfer agreement.
  • 網站簡介 (Quickstart Guide)
  • 使用手冊 (Instruction Manual)
  • 線上預約服務 (Booking Service)
  • 方案一:臺灣大學計算機中心帳號登入
    (With C&INC Email Account)
  • 方案二:ORCID帳號登入 (With ORCID)
  • 方案一:定期更新ORCID者,以ID匯入 (Search for identifier (ORCID))
  • 方案二:自行建檔 (Default mode Submission)
  • 方案三:學科館員協助匯入 (Email worklist to subject librarians)
Build with DSpace-CRIS - Extension maintained and optimized by Logo 4SCIENCE Feedback